Clinic
Holyoke Medical Center, INC.
Holyoke Medical Center, INC. was paid $125.05M by Medicaid between Jan 2018 and Dec 2024, across 523 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 12% of everything it billed.
33Billing provider infoHOLYOKE MEDICAL CENTER, INC.
HOLYOKE, MA 01040
HOLYOKE, MA 01040
33aNPI1750395737assigned 07/28/2006
33bProvider typeAdult Mental Health Clinic/Center
28Total paid$125.05M
24GClaims3,244,490
24DCodes billed523
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Adult Mental Health Clinic/Center providers in Massachusetts
Rank by total paid#1 of 20
Median peer was paid$222K
This provider vs. median564×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 526,267 | $19.58M | |
| 2019 | 571,773 | $17.64M | |
| 2020 | 435,446 | $14.22M | |
| 2021 | 439,173 | $16.60M | |
| 2022 | 453,618 | $19.84M | |
| 2023 | 463,994 | $21.17M | |
| 2024incomplete | 354,219 | $16.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 12% | 100,828 | 83,311 | $15.51M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.9% | 78,353 | 72,062 | $12.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 73,916 | 66,166 | $11.58M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.1% | 23,031 | 19,477 | $7.68M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 59,396 | 17,832 | $3.51M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 19,995 | 15,551 | $3.30M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.5% | 111,736 | 82,186 | $3.09M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.2% | 71,287 | 67,089 | $2.74M |
| J2357 | Injection, omalizumab, 5 mg | 2.0% | 1,400 | 592 | $2.55M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.0% | 14,483 | 14,089 | $2.49M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 5,698 | 5,300 | $2.29M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.5% | 59,191 | 54,504 | $1.83M |
511 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 10,672 | $1.72M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 12,370 | $1.66M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.3% | 3,474 | $1.60M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 8,078 | $1.49M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 8,091 | $1.48M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 12,197 | $1.47M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 15,307 | $1.38M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.1% | 701 | $1.35M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 29,924 | $1.29M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 17,658 | $1.23M |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 18,409 | $1.06M |
| 20610 | <1% | 9,570 | $1.02M | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 15,828 | $969K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,195 | $957K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 2,246 | $907K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,969 | $894K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,714 | $893K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,959 | $869K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 5,824 | $860K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,716 | $840K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 1,847 | $777K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 149,735 | $689K |
| 93971 | <1% | 3,773 | $654K | |
| 76830 | Ultrasound, transvaginal | <1% | 6,670 | $648K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,867 | $606K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 7,837 | $572K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 20,025 | $571K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 5,433 | $554K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,691 | $538K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 31,160 | $535K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 52,437 | $527K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,940 | $524K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,217 | $517K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,809 | $492K |
| 76775 | <1% | 4,540 | $487K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 18,449 | $475K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,974 | $473K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17,962 | $465K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 15,953 | $384K |
| 76642 | <1% | 3,957 | $372K | |
| 80053 | Comprehensive metabolic panel | <1% | 101,635 | $350K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 16,443 | $346K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 18,253 | $328K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,368 | $318K |
| 95886 | <1% | 1,806 | $316K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 6,646 | $310K |
| 93970 | <1% | 1,309 | $263K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 22,678 | $253K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,232 | $246K |
| 76536 | <1% | 2,211 | $240K | |
| 97803 | <1% | 3,851 | $238K | |
| 86481 | <1% | 3,740 | $231K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12,541 | $226K |
| 76801 | <1% | 2,055 | $220K | |
| 95806 | <1% | 1,835 | $220K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,418 | $219K |
| 94060 | <1% | 3,427 | $214K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 26,212 | $213K |
| 92567 | <1% | 5,059 | $212K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,197 | $201K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,753 | $200K |
| 93017 | <1% | 2,094 | $195K | |
| ATP14 | <1% | 25,932 | $194K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 3,850 | $194K |
| 52000 | <1% | 680 | $191K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,280 | $188K |
| 97161 | <1% | 5,029 | $187K | |
| 84484 | <1% | 27,591 | $182K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,268 | $180K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 863 | $179K |
| 72100 | <1% | 5,801 | $178K | |
| 99223 | Prolong inpt eval add15 m | <1% | 2,969 | $177K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 31,296 | $174K |
| 82607 | <1% | 19,916 | $174K | |
| 97162 | <1% | 4,198 | $165K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 43,680 | $165K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 4,865 | $163K |
| 87480 | <1% | 10,011 | $163K | |
| 87510 | <1% | 10,040 | $162K | |
| 87660 | <1% | 9,932 | $162K | |
| 80061 | Lipid panel | <1% | 58,925 | $160K |
| 73564 | <1% | 5,643 | $160K | |
| 92588 | <1% | 1,426 | $158K | |
| 50590 | <1% | 131 | $154K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 4,831 | $153K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,564 | $152K |
| 81025 | <1% | 23,028 | $148K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 6,064 | $148K |
| 73130 | <1% | 7,893 | $146K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 566 | $146K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 47,538 | $146K |
| 73030 | <1% | 7,145 | $145K | |
| G0378 | Hospital observation service, per hour | <1% | 6,402 | $144K |
| 92557 | <1% | 1,987 | $144K | |
| 92579 | <1% | 1,762 | $143K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,177 | $142K |
| 88342 | <1% | 6,155 | $142K | |
| 83690 | <1% | 29,719 | $140K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 526 | $137K |
| 82746 | <1% | 15,924 | $136K | |
| 86803 | <1% | 13,829 | $136K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 456 | $136K |
| 83880 | <1% | 8,773 | $135K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,794 | $134K |
| 87631 | <1% | 1,401 | $132K | |
| 97802 | <1% | 1,965 | $132K | |
| 84702 | <1% | 10,316 | $131K | |
| 77062 | <1% | 1,390 | $131K | |
| 73630 | <1% | 5,886 | $131K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,565 | $125K |
| 83970 | <1% | 5,992 | $125K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 786 | $121K |
| 86780 | <1% | 11,287 | $121K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 56,459 | $120K |
| 88142 | <1% | 7,535 | $120K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,751 | $119K |
| 85027 | <1% | 29,733 | $117K | |
| 71250 | <1% | 2,351 | $116K | |
| 97804 | <1% | 2,047 | $116K | |
| 82947 | <1% | 54,551 | $111K | |
| 82728 | <1% | 12,829 | $109K | |
| 71045 | Radiologic examination, chest; single view | <1% | 18,280 | $102K |
| 94727 | <1% | 3,371 | $102K | |
| 83735 | <1% | 24,838 | $101K | |
| 81001 | <1% | 45,004 | $97K | |
| 87536 | <1% | 1,792 | $96K | |
| V5160 | Dispensing fee, binaural | <1% | 258 | $94K |
| 77080 | <1% | 1,965 | $94K | |
| 80076 | <1% | 46,653 | $91K | |
| 10060 | <1% | 568 | $91K | |
| 73610 | <1% | 4,908 | $90K | |
| 85610 | <1% | 42,247 | $90K | |
| V5266 | Battery for use in hearing device | <1% | 2,168 | $90K |
| 84439 | <1% | 16,542 | $89K | |
| 83013 | <1% | 1,731 | $85K | |
| 87340 | <1% | 10,724 | $85K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,338 | $84K |
| 87088 | <1% | 14,916 | $82K | |
| ATP15 | <1% | 10,001 | $82K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 245 | $81K |
| 74246 | <1% | 653 | $80K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 435 | $79K |
| 73110 | <1% | 4,299 | $78K | |
| 73502 | <1% | 4,009 | $78K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 5,551 | $76K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 817 | $73K |
| 77065 | Tomosynthesis, mammo | <1% | 1,980 | $72K |
| 87071 | <1% | 8,246 | $70K | |
| 96415 | <1% | 325 | $69K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,887 | $69K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,990 | $68K |
| 86706 | <1% | 8,832 | $67K | |
| 87040 | <1% | 7,543 | $66K | |
| 86704 | <1% | 7,588 | $65K | |
| 97035 | <1% | 1,330 | $64K | |
| 93975 | <1% | 624 | $64K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,604 | $63K |
| 95811 | <1% | 133 | $63K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,964 | $63K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,814 | $61K |
| 86140 | <1% | 17,930 | $61K | |
| 76981 | <1% | 1,100 | $58K | |
| 80050 | General health panel | <1% | 3,649 | $58K |
| 83655 | <1% | 5,131 | $58K | |
| 74018 | <1% | 2,717 | $57K | |
| 81003 | <1% | 34,166 | $56K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,509 | $56K |
| ATP08 | <1% | 10,572 | $56K | |
| V5261 | Hearing aid, digital, binaural, bte | <1% | 82 | $54K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,331 | $54K |
| 83540 | <1% | 12,780 | $53K | |
| 94729 | <1% | 3,384 | $53K | |
| ATP17 | <1% | 12,265 | $50K | |
| 73560 | <1% | 4,804 | $50K | |
| 92587 | <1% | 409 | $49K | |
| 84153 | <1% | 3,781 | $48K | |
| 82043 | <1% | 17,454 | $48K | |
| 83605 | <1% | 7,024 | $48K | |
| 80305 | <1% | 5,047 | $47K | |
| 84425 | <1% | 3,016 | $46K | |
| 80051 | <1% | 31,612 | $45K | |
| 12001 | <1% | 244 | $45K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,041 | $43K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,118 | $43K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 578 | $42K |
| 87186 | <1% | 7,324 | $42K | |
| 82565 | <1% | 35,458 | $41K | |
| 90715 | <1% | 1,771 | $40K | |
| ATP07 | <1% | 5,951 | $38K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,080 | $37K |
| 85730 | <1% | 9,841 | $35K | |
| 58100 | <1% | 350 | $35K | |
| 82784 | <1% | 4,310 | $34K | |
| 84520 | <1% | 34,251 | $34K | |
| ATP18 | <1% | 4,658 | $34K | |
| 86038 | <1% | 4,226 | $34K | |
| 72050 | <1% | 524 | $33K | |
| 85379 | <1% | 4,764 | $33K | |
| 86850 | <1% | 4,275 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 84,551 | $32K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,745 | $32K |
| 83550 | <1% | 5,616 | $31K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 69 | $30K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,347 | $29K |
| 81513 | <1% | 262 | $29K | |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | <1% | 478 | $28K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,388 | $28K |
| 84403 | <1% | 1,788 | $27K | |
| 85652 | <1% | 15,909 | $27K | |
| 86360 | <1% | 1,261 | $27K | |
| 86618 | <1% | 2,509 | $27K | |
| 73562 | <1% | 1,508 | $27K | |
| 83525 | <1% | 3,229 | $26K | |
| 29125 | <1% | 188 | $26K | |
| 59025 | Fetal non-stress test | <1% | 138 | $26K |
| 51798 | <1% | 6,597 | $25K | |
| 84590 | <1% | 2,995 | $25K | |
| 87070 | <1% | 3,807 | $24K | |
| ATP03 | <1% | 6,509 | $24K | |
| 43775 | <1% | 35 | $24K | |
| 83516 | <1% | 1,445 | $24K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,896 | $23K |
| 84630 | <1% | 2,852 | $23K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,888 | $22K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 40 | $21K |
| 64721 | <1% | 95 | $21K | |
| 88112 | <1% | 731 | $21K | |
| 85007 | <1% | 8,647 | $21K | |
| 77061 | <1% | 305 | $21K | |
| 74240 | <1% | 139 | $21K | |
| 86709 | <1% | 2,676 | $21K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,849 | $20K |
| 84146 | <1% | 1,280 | $19K | |
| 93225 | <1% | 573 | $19K | |
| 86235 | <1% | 1,072 | $19K | |
| 86762 | <1% | 1,526 | $19K | |
| V5020 | Conformity evaluation | <1% | 275 | $18K |
| 86900 | <1% | 4,955 | $18K | |
| 93016 | <1% | 2,141 | $18K | |
| 86359 | <1% | 1,249 | $18K | |
| 73080 | <1% | 887 | $18K | |
| 72110 | <1% | 507 | $17K | |
| Q3014 | Telehealth originating site facility fee | <1% | 5,328 | $17K |
| 86787 | <1% | 1,444 | $17K | |
| 76813 | <1% | 100 | $15K | |
| 95909 | <1% | 238 | $15K | |
| 84402 | <1% | 836 | $15K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 172 | $15K |
| 86160 | <1% | 1,444 | $14K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 71 | $14K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,060 | $14K |
| 99443 | <1% | 879 | $14K | |
| 99442 | <1% | 1,287 | $14K | |
| 86003 | <1% | 186 | $14K | |
| 99221 | <1% | 295 | $14K | |
| 95911 | <1% | 152 | $14K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,022 | $13K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 234 | $13K |
| 87077 | <1% | 3,176 | $13K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 64 | $13K |
| 57454 | <1% | 101 | $12K | |
| 93226 | <1% | 645 | $12K | |
| 86901 | <1% | 4,814 | $12K | |
| 82077 | <1% | 2,757 | $12K | |
| 95885 | <1% | 51 | $12K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 37 | $12K |
| 00731 | <1% | 163 | $11K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 132 | $11K |
| 86431 | <1% | 2,729 | $11K | |
| 93018 | <1% | 2,137 | $11K | |
| 88304 | <1% | 1,877 | $11K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 55 | $11K |
| 82570 | <1% | 3,806 | $10K | |
| 73620 | <1% | 630 | $10K | |
| 71271 | <1% | 246 | $10K | |
| 86255 | <1% | 1,192 | $10K | |
| 99205 | Prolong outpt/office vis | <1% | 96 | $10K |
| 97014 | <1% | 287 | $10K | |
| 72040 | <1% | 304 | $10K | |
| 86200 | <1% | 1,166 | $10K | |
| 82550 | <1% | 5,098 | $10K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,916 | $10K |
| 86334 | <1% | 830 | $10K | |
| 97033 | <1% | 154 | $9K | |
| 88307 | <1% | 167 | $9K | |
| 94010 | <1% | 151 | $9K | |
| 00811 | <1% | 133 | $9K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 44 | $9K |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 318 | $9K |
| 86364 | <1% | 736 | $9K | |
| 83001 | <1% | 607 | $8K | |
| 83721 | <1% | 2,099 | $8K | |
| 80179 | <1% | 1,010 | $8K | |
| 43659 | <1% | 29 | $8K | |
| 64615 | <1% | 63 | $8K | |
| 87338 | <1% | 896 | $8K | |
| 87507 | <1% | 27 | $8K | |
| ATP11 | <1% | 1,333 | $7K | |
| 29130 | <1% | 60 | $7K | |
| 76770 | <1% | 76 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 264 | $7K |
| 73565 | <1% | 2,600 | $7K | |
| 87205 | <1% | 2,672 | $7K | |
| 97165 | <1% | 86 | $7K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 677 | $7K |
| 96127 | <1% | 170 | $7K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,631 | $7K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 350 | $7K |
| 43249 | <1% | 44 | $7K | |
| 71101 | <1% | 365 | $7K | |
| 86376 | <1% | 677 | $6K | |
| 82105 | <1% | 638 | $6K | |
| 87481 | <1% | 234 | $6K | |
| 76942 | <1% | 62 | $6K | |
| ATP02 | <1% | 2,306 | $6K | |
| 86790 | <1% | 760 | $6K | |
| 84703 | <1% | 862 | $6K | |
| 84156 | <1% | 2,876 | $6K | |
| 95250 | <1% | 126 | $6K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 20 | $5K |
| 70486 | <1% | 141 | $5K | |
| 76870 | <1% | 50 | $5K | |
| 92552 | <1% | 132 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,817 | $5K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 67 | $5K |
| 96367 | <1% | 446 | $5K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 92 | $5K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,372 | $5K |
| 80164 | <1% | 925 | $5K | |
| 73600 | <1% | 310 | $5K | |
| 84460 | <1% | 3,625 | $5K | |
| 82248 | <1% | 2,734 | $5K | |
| 73120 | <1% | 266 | $5K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 48 | $5K |
| 80143 | <1% | 745 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 173 | $4K |
| 87902 | <1% | 56 | $4K | |
| 84450 | <1% | 3,342 | $4K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 71 | $4K |
| 84550 | <1% | 2,974 | $4K | |
| 84100 | <1% | 3,761 | $4K | |
| 93297 | <1% | 507 | $4K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 506 | $4K |
| 86800 | <1% | 441 | $4K | |
| 83615 | <1% | 2,269 | $4K | |
| 82652 | <1% | 147 | $4K | |
| 86708 | <1% | 437 | $4K | |
| 86225 | <1% | 475 | $4K | |
| 93227 | <1% | 407 | $4K | |
| 87147 | <1% | 973 | $4K | |
| 64493 | <1% | 36 | $4K | |
| 97116 | <1% | 131 | $4K | |
| 96376 | <1% | 2,776 | $4K | |
| 92593 | <1% | 112 | $4K | |
| 84436 | <1% | 1,026 | $3K | |
| ATP10 | <1% | 690 | $3K | |
| 86735 | <1% | 357 | $3K | |
| 88141 | <1% | 174 | $3K | |
| 86765 | <1% | 362 | $3K | |
| ATP09 | <1% | 733 | $3K | |
| ATP04 | <1% | 769 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,176 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,163 | $3K |
| 84165 | <1% | 514 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,375 | $3K |
| 73590 | <1% | 232 | $3K | |
| 90686 | <1% | 188 | $3K | |
| 82310 | <1% | 3,051 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 313 | $3K |
| 86592 | <1% | 940 | $3K | |
| 87581 | <1% | 112 | $3K | |
| 87486 | <1% | 112 | $3K | |
| 82803 | <1% | 167 | $3K | |
| 95251 | <1% | 216 | $3K | |
| 85045 | <1% | 1,197 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,062 | $3K |
| 00813 | <1% | 31 | $3K | |
| 99385 | <1% | 27 | $3K | |
| 82950 | <1% | 536 | $3K | |
| 83520 | <1% | 55 | $3K | |
| 85018 | <1% | 1,449 | $2K | |
| 87046 | <1% | 312 | $2K | |
| 84481 | <1% | 219 | $2K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 33 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,500 | $2K |
| 82553 | <1% | 423 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 345 | $2K |
| 90480 | <1% | 47 | $2K | |
| 73140 | <1% | 131 | $2K | |
| 88313 | <1% | 340 | $2K | |
| 93925 | <1% | 27 | $2K | |
| ATP16 | <1% | 267 | $2K | |
| 99386 | <1% | 14 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,141 | $2K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 578 | $2K |
| 93880 | <1% | 15 | $2K | |
| 93296 | <1% | 63 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 46 | $2K |
| 84480 | <1% | 171 | $2K | |
| 73090 | <1% | 91 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 14 | $2K |
| 93458 | <1% | 12 | $2K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 61 | $2K |
| 82785 | <1% | 158 | $1K | |
| 83010 | <1% | 156 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 421 | $1K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 78 | $1K |
| 99441 | <1% | 286 | $1K | |
| 72070 | <1% | 36 | $1K | |
| ATP05 | <1% | 317 | $1K | |
| ATP06 | <1% | 382 | $1K | |
| 93244 | <1% | 106 | $1K | |
| 82040 | <1% | 1,253 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 681 | $1K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 423 | $1K |
| 83002 | <1% | 118 | $1K | |
| 86039 | <1% | 174 | $1K | |
| 82150 | <1% | 269 | $1K | |
| 82533 | <1% | 114 | $1K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 52 | $1K |
| 82024 | <1% | 59 | $1K | |
| 83883 | <1% | 124 | $1K | |
| 92591 | <1% | 25 | $1K | |
| 90656 | <1% | 210 | $1K | |
| 85014 | <1% | 541 | $999.73 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,647 | $995.65 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,199 | $934.88 |
| 82140 | <1% | 110 | $920.22 | |
| 87045 | <1% | 133 | $839.03 | |
| 64494 | <1% | 27 | $813.65 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 73 | $770.16 |
| 72170 | <1% | 55 | $761.16 | |
| 82172 | <1% | 66 | $751.53 | |
| 72072 | <1% | 24 | $725.97 | |
| 80178 | <1% | 237 | $712.65 | |
| 82977 | <1% | 514 | $711.19 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,113 | $687.96 |
| 94644 | <1% | 581 | $677.31 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 952 | $651.82 |
| 87255 | <1% | 41 | $630.00 | |
| 97597 | <1% | 33 | $609.52 | |
| 86769 | <1% | 62 | $607.04 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 181 | $602.25 |
| 86141 | <1% | 56 | $599.33 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 26 | $595.95 |
| 87324 | <1% | 84 | $584.52 | |
| 97760 | <1% | 16 | $580.97 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 339 | $562.71 |
| 82272 | <1% | 317 | $556.75 | |
| 46600 | <1% | 38 | $526.31 | |
| 27096 | <1% | 14 | $520.87 | |
| 93242 | <1% | 130 | $502.33 | |
| 92556 | <1% | 26 | $486.01 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 193 | $483.75 |
| 74220 | <1% | 13 | $474.18 | |
| 86147 | <1% | 29 | $449.94 | |
| 84145 | <1% | 62 | $415.48 | |
| 87625 | <1% | 13 | $392.23 | |
| G0008 | Administration of influenza virus vaccine | <1% | 163 | $380.18 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 422 | $371.50 |
| 93356 | <1% | 200 | $349.52 | |
| 81002 | <1% | 165 | $320.37 | |
| 85060 | <1% | 31 | $271.75 | |
| 86308 | <1% | 55 | $256.65 | |
| V5275 | Ear impression, each | <1% | 12 | $253.53 |
| 82009 | <1% | 107 | $237.66 | |
| 20550 | <1% | 12 | $229.46 | |
| 86300 | <1% | 29 | $222.39 | |
| 80185 | <1% | 31 | $218.72 | |
| 87210 | <1% | 51 | $184.90 | |
| 82378 | <1% | 29 | $171.18 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 15 | $159.56 |
| 94664 | <1% | 173 | $157.37 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 92 | $156.32 |
| 87209 | <1% | 16 | $150.50 | |
| 89050 | <1% | 55 | $145.51 | |
| 82985 | <1% | 15 | $144.61 | |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | <1% | 22 | $135.52 |
| 88311 | <1% | 26 | $133.74 | |
| 82274 | <1% | 13 | $87.06 | |
| 96160 | <1% | 48 | $83.04 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 63 | $76.36 |
| 87177 | <1% | 16 | $74.50 | |
| 90732 | <1% | 14 | $71.26 | |
| ATP13 | <1% | 27 | $65.34 | |
| 82340 | <1% | 13 | $61.55 | |
| 99152 | <1% | 20 | $50.37 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 31 | $33.64 |
| 82465 | <1% | 14 | $26.88 | |
| 82247 | <1% | 39 | $25.90 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 92 | $23.15 |
| 0011A | <1% | 27 | $22.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 18 | $20.28 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 60 | $12.57 |
| S0028 | Injection, famotidine, 20 mg | <1% | 80 | $6.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 97 | $5.20 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 338 | $5.11 |
| 81596 | 0% | 72 | $0.00 | |
| 0012A | 0% | 18 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 132 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 14 | $0.00 |
| C1769 | Guide wire | 0% | 14 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 12 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 514 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 450 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 50 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 95 | $0.00 |
| 90661 | 0% | 113 | $0.00 | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | 0% | 15 | $0.00 |
| 91321 | 0% | 24 | $0.00 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSILVA, PAUL (VICE PRESIDENT OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Holyoke Medical Center, INC. | Holyoke, MA | $922K |
| Holyoke Medical Center, INC. | Holyoke, MA | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.